1P-ETH-LAD

Structural formula
General
Surname	1P-ETH-LAD
other names	(8 β ) - N , N , 6-triethyl-1-propionyl-9,10-didehydroergoline-8-carboxamide ( IUPAC ) ; 1-propionyl-6-ethyl-6-nor-lysergic acid diethyamide; 1-propionyl-ETH-LAD;
Molecular formula	C 24 H 31 N 3 O 2
External identifiers / databases
PubChem	119025859
Wikidata	Q27279820
Drug information
Mechanism of action	Agonist at the serotonin (5-HT 2 ) receptors
properties
Molar mass	393.53 g mol −1
safety instructions
GHS hazard labeling ; no classification available
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

1P-ETH-LAD (English 1- propionyl- eth yl - nor- l ysergic a cid d iethylamide ) is a chemically produced derivative of lysergic acid , which occurs naturally as an ergot alkaloid , and an analogue of LSD , ETH-LAD and 1P -LSD . Even in very small doses , it produces long-lasting hallucinogenic effects. Pharmacologically, 1P-ETH-LAD belongs to the group of serotonin-related psychedelic substances.

chemistry

Chemically, 1P-ETH-LAD belongs to the Ergoline structural class . The tetracyclic ergoline is characteristic of the chemical structure of ergot alkaloids . The ergolines found in nature are methylated on the nitrogen in position 6 of the ergoline system . In contrast to ETH-LAD, 1P-ETH-LAD has an additional N ¹ - propionyl group and, in contrast to 1P-LSD, an N ⁶ - ethyl group instead of an N ⁶ - methyl group .

Basic body of the Ergoline
ETH-LAD structural formula
Structural formula of 1P-ETH-LAD
Structural formula of 1P-LSD
LSD structural formula

pharmacology

1P-ETH-LAD hydrolyses (in the same way or similar to 1P-LSD ) in the body, splitting off propionic acid to form ETH-LAD, as an LC-MS analysis showed that ETH-LAD is formed when 1P-ETH-LAD is in human blood serum is incubated. It is therefore assumed that the profile will be similar to that of ETH-LAD.

literature

Simon D. Brandt, Pierce V. Kavanagh et al. a .: Return of the lysergamides. Part III: Analytical characterization of N ⁶ -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). In: Drug Testing and Analysis. 2017, doi : 10.1002 / dta.2196 .
Lea Wagmann, Lilian HJ Richter a. a .: In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. In: Analytical and Bioanalytical Chemistry. 2019, doi : 10.1007 / s00216-018-1558-9 .

Web links

isomerdesign.com: 1P-ETH-LAD (English)

Individual evidence

↑ ^a ^b Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal, Alexander Stratford, Simon P. Elliott, Khoa Hoang, Jason Wallach, Adam L. Halberstadt: Return of the lysergamides. Part I: Analytical and behavioral characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). In: Drug Testing and Analysis. 2015, pp. 891–902, doi : 10.1002 / dta.1884 .
^ ^A ^b F. Schifano, L. Orsolini, D. Papanti, J. Corkery: NPS: Medical Consequences Associated with Their Intake. In: Current Topics in Behavioral Neurosciences. Volume 32, 2017, pp. 351-380, doi : 10.1007 / 7854_2016_15 , PMID 27272067 .
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Lea Wagmann, Lilian HJ Richter a. a .: In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. In: Analytical and Bioanalytical Chemistry. , doi : 10.1007 / s00216-018-1558-9 .
↑ Simon D. Brandt, Pierce V. Kavanagh et al. a .: Return of the lysergamides. Part III: Analytical characterization of N ⁶ -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). In: Drug Testing and Analysis. 2017, doi : 10.1002 / dta.2196 .

[DOI10.1002/dta.1884-1] Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal, Alexander Stratford, Simon P. Elliott, Khoa Hoang, Jason Wallach, Adam L. Halberstadt: Return of the lysergamides. Part I: Analytical and behavioral characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). In: Drug Testing and Analysis. 2015, pp. 891–902, doi : 10.1002 / dta.1884 .

[PMID27272067-2] A ^b F. Schifano, L. Orsolini, D. Papanti, J. Corkery: NPS: Medical Consequences Associated with Their Intake. In: Current Topics in Behavioral Neurosciences. Volume 32, 2017, pp. 351-380, doi : 10.1007 / 7854_2016_15 , PMID 27272067 .

[NV-3] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[DOI10.1007/s00216-018-1558-9-4] Lea Wagmann, Lilian HJ Richter a. a .: In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. In: Analytical and Bioanalytical Chemistry. , doi : 10.1007 / s00216-018-1558-9 .

[5] Simon D. Brandt, Pierce V. Kavanagh et al. a .: Return of the lysergamides. Part III: Analytical characterization of N ⁶ -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). In: Drug Testing and Analysis. 2017, doi : 10.1002 / dta.2196 .